Pharmigene, Inc. (TPEX:7595)
Taiwan
· Delayed Price · Currency is TWD 10.00
+0.10 (1.01%)
Apr 29, 2026, 2:00 PM CST
Pharmigene Revenue
Pharmigene had revenue of 80.68M TWD in the half year ending June 30, 2025, with 50.57% growth. This brings the company's revenue in the last twelve months to 149.25M, up 17.45% year-over-year. In the year 2024, Pharmigene had annual revenue of 116.53M, down -12.19%.
Revenue (ttm)
149.25M
Revenue Growth
+17.45%
P/S Ratio
3.35
Revenue / Employee
n/a
Employees
n/a
Market Cap
499.60M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Welgene Biotech | 375.94M |
| Sofiva Genomics | 385.71M |
| Puriblood Medical | 117.35M |
| Kim Forest Enterprise | 549.14M |
| Genetics Generation Advancement | 603.11M |
| DIVA Laboratories | 868.84M |
| BIONET | 1.24B |